- Home
- ZTEK vs TENX Comparison
ZTEK vs TENX Comparison
Compare ZTEK & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | TENX |
|---|---|---|
| Founded | 2008 | 1967 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 56.2M |
| IPO Year | 2022 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | TENX |
|---|---|---|
| Price | $0.50 | $14.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 79.6K | ★ 474.0K |
| Earning Date | 02-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $4.64 |
| 52 Week High | $1.84 | $18.38 |
Technical Indicators
Market Signals| Indicator | ZTEK | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 49.50 |
| Support Level | N/A | $12.71 |
| Resistance Level | $0.57 | $16.61 |
| Average True Range (ATR) | 0.04 | 1.14 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 34.32 | 28.57 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.